retatrutide side effects clinical trials 2025 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide clinical trial done! Now

N-acetyl cysteine as an adjunct in the treatment of tuberculosis

The ideal candidate is generally an adult with a body mass index (BMI) of 27 or higher, with at least one weight-related health issue, or a BMI of 30 or greater without any additional health conditions

Huan Cheng, Z

The next few years will determine whether this hope translates into real help for patients and families

The commercial features a polar bear discovering his preference for Pepsi Zero Sugar over Coke Zero Sugar in a blind taste test, set to Queens I Want to Break Free. The ad arrives as demand for zero-sugar sodas accelerates among health-conscious consumers, with Pepsi Zero Sugar posting 30.8% growth in 2025, nearly double the zero-sugar cola category